The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'August 2020'. If you still can't find what you are looking for, try using the search box.
Oxford, UK: Vaccitech Limited, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation technology platform to protect against COVID-19. The grant is part of the UKRI-NIHR COVID-19 rapid response rolling call for proposals with potential to deliver public health impacts within 12 months.
Preclinical data indicate Vaccitech’s new platform induces leading antibody and cell-mediated immune responses, two arms of the immune system known to protect against disease, when compared with the adenoviral platforms currently in vaccine trials for COVID-19. The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech’s research efforts.
Vaccitech was awarded £1 ...
Read the rest of entry »
The first in the series will be hosted by James Brayer — Associate Director, Market Development, Oxford Nanopore Technologies — on 8th September at 5pm (BST). Join James for an introduction to nanopore sequencing and be sure to bring your questions along for a Q&A which will follow the presentation.
AMSBIO announce a new service designed to provide high-content cytometry data on cells and tissues enabling the automated analysis of fluorescent biomarkers on living cells or long-term stored biobanked cells and tissues.
Leveraging the innovative ChipCytometry platform, AMSBIO is able to offer a complete workflow solution (products and services) for high-content cytometry on cells and tissues, from sample preparation and biobanking to biomarker analysis and data mining.
The ChipCytometry platform operates by immobilizing cells in microfluidic chips, which are later stained with antibodies for multiplex biomarker detection. Using the ChipCytometry platform - AMSBIO can offer quantitative analysis of a virtually unlimited number of protein biomarkers in a single sample. AMSBIO is also to offer custom assays facilitating analysis of almost any antibody / biomarker target. Not only can this technology deliver quantitative biomarker analysis but it ca ...
Overcoming challenges for small molecules - webinar
Nominated candidates entering clinical development often have sub-optimal physicochemical, biopharmaceutic or DMPK properties for oral delivery. Development teams are challenged with how to understand the properties of new drug candidates, how to design the appropriate formulation strategy and how to move quickly and successfully into early phase clinical trials. Along the way, it is important to identify developability risks and take steps to mitigate these factors, balanced carefully against time and cost investments.
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
Dr Vanessa Zann, Senior Drug Development Consultant, Quotient Sciences
Dr Shriram Pathak, Senior Research Fellow, Scientific ...
Redcar, UK: Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced the availability of SARS-CoV-2 neutralizing antibodies derived from individuals infected with COVID-19. The antibodies, originally generated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. They are now available to scientists and diagnostic developers worldwide via Absolute Antibody’s online catalog.
The new antibodies were generated from the blood cells of an infected COVID-19 patient and have shown in a recent article to display neutralizing activity against SARS-CoV-2, the coronavirus that causes COVID-19. Two antibody clones (CV1 and CV30) each bound the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2. Both antibodies are now available in a variety of spe ...
London, UK: The Royal Academy of Engineering has awarded 19 individuals and teams of engineers with the President's Special Awards for Pandemic Service for exceptional engineering achievements in tackling COVID-19 throughout the UK.
The awards have been made to teams, organisations, individuals, collaborations and projects across all technical specialities, disciplines and career stages within the UK engineering community who have contributed to addressing the challenges of the COVID-19 pandemic. Specially commissioned silver medals will be presented to all 19 winners later this year.
The winners are:
Ventilator Challenge UK Consortium. Dick Elsy CBE led the initiative to combine the knowledge and skills of 33 UK technology and engineering businesses across the aerospace, automotive and medical sectors, to produce more than 13,000 Smiths and Penlon ventilator devices for the NHS.
University College London-Ventura CPAP breathing aids we ...
Oxford, UK: Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the signing of a licensing agreement with Roche providing Celleron exclusive world-wide rights for the clinical development, manufacturing and commercialization of emactuzumab. The closing is expected by end of 2020 after all conditions have been met.
This license agreement of emactuzumab demonstrates Celleron’s commitment to cancer medicine development and its transformational potential for patients inflicted with cancer. Emactuzumab is a monoclonal antibody designed to target and deplete macrophages in the tumor tissue. It has shown a favourable safety profile in patients and very encouraging efficacy for diffuse tenosynovial giant cell tumour (TGCT), a rare disease characterised by the proliferation of macrophages in the synovial tissue in the joint and tendon sheath.
Professor Nick La Thangue, Chief Executive Officer of Celleron Therapeutics, com ...
Oxford, UK: In the Times Future of Healthcare supplement, Isansys’ Patient Status Engine (PSE), a smart clinical data collection, analysis and prediction platform, was acclaimed for playing a crucial role in helping care teams around the world combat the Coronavirus. Using real-time patient data to track the course of the disease, the unique clinical infrastructure aims to improve early detection of Covid-19 – and many other conditions – in patients in hospital and home settings.
The PSE uses wearable body-worn sensors to continuously and wirelessly monitor vital signs including heart rate, ECG patterns, respiration rate, blood pressure, temperature and oxygen saturation. Advanced analytic techniques can use these high resolution and highly correlated physiological signals to indicate the presence of the virus, potentially before symptoms are detectable by other methods. These digital biomarkers provide a valuable stream of health data which can enable care teams to better unders ...
Foster City, Calif., and Nottingham, UK: ANA Therapeutics, a Silicon Valley-based biotech startup, and Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Health Organization’s List of Essential Medicines and has been used for decades to ...
Kent, UK: A proposal that could bring £60million investment into the life sciences sector in Kent has taken a significant stride forward by securing £50,000 to develop the bid further. The money is seedcorn funding via UK Research and Innovation’s flagship £236m Strength in Places Fund.
If the bid is successful, it will provide funding for an ‘Accelerated Medicines Design and Development’ (AMDD) project to be based in Discovery Park, Sandwich. This would build on an existing concentration of research excellence associated with Pfizer and other companies at Discovery Park, alongside a network of partners.
Advanced digital tools are transforming our understanding of disease and the drug discovery process and the AMDD project intends to focus on the potential of digital technology to speed up the ‘development’ phases of work on new medicines. Developing a medicine is currently a physical laboratory and experiment intensive process, ...
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.